Oct 01, 2013
The FDA's Drug Safety and Risk Management Advisory Committee has been evaluating the status of
hydrocodone combination drugs, such as Vicodin®, Lortab®, Norco®, and Vicoprofen®. In January
2013, this committee voted 19 to 10 in favor of reclassifying combination medications containing
hydrocodone from Schedule III drugs under the Controlled Substances Act to Schedule II. This would
impose significantly stricter prescribing rules on drugs containing hydrocodone.